Codex DNA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Guidance
22 mars 2022 16h05 HE
|
Codex DNA, Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the fourth quarter and...
Codex DNA Announces Registration and Webcast Information for Upcoming R&D Webinar on March 29, 2022
03 mars 2022 08h03 HE
|
Codex DNA, Inc.
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced details for its first Investor R&D...
Codex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022
02 mars 2022 08h03 HE
|
Codex DNA, Inc.
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its fourth quarter 2021...
Codex DNA to Present at the Cowen 42nd Annual Healthcare Conference
24 févr. 2022 08h03 HE
|
Codex DNA, Inc.
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief...
Codex DNA to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
09 févr. 2022 08h03 HE
|
Codex DNA, Inc.
SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that members of its management team will be...
Codex DNA Showcases Potential of Groundbreaking SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and Therapeutics
18 janv. 2022 08h03 HE
|
Codex DNA, Inc.
Proprietary short oligo ligation assembly (SOLA) technology used to enzymatically synthesize DNA fragments for the construction of full-length H1 and N1 genes from influenza A virusInitial performance...
Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and Development of mRNA-based Vaccines and Biotherapies
10 janv. 2022 06h50 HE
|
Codex DNA, Inc.
Pfizer and Codex DNA agree to strategic, multiyear, early access research collaboration, leveraging Codex DNA’s novel enzymatic DNA synthesis (EDS) technologyPfizer’s successful development and...
Codex DNA Expands Catalog of COVID-19 Tools with Release of Full-Length Synthetic Genome for SARS-CoV-2 Omicron Variant
23 déc. 2021 08h03 HE
|
Codex DNA, Inc.
SAN DIEGO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the release of a new full-length synthetic...
Codex DNA Announces Commercial Availability of Automated mRNA Synthesis Kit with Integrated Capping Technology for BioXp™ System
29 nov. 2021 08h03 HE
|
Codex DNA, Inc.
Proven CleanCap® reagent technology from TriLink BioTechnologies delivers significant time and cost savings for mRNA-based vaccine and therapeutic applicationsCodex DNA scientists to share latest data...
Codex DNA to Present at the Jefferies London Healthcare Conference
11 nov. 2021 08h03 HE
|
Codex DNA, Inc.
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief...